Thesis icon

Thesis

Identifying novel neuromodulator targets of human cognition

Abstract:
Impaired cognition is often overlooked in the clinical management of depression, despite being a principal modulator of perceived disability and quality of life within depression (Knight, Air, & Baune, 2018; Knight, Lyrtzis, & Baune, 2020; Koenig, Bhalla, & Butters, 2014; Naismith, Longley, Scott, & Hickie, 2007). There is an outstanding need for new treatments to address this unmet clinical need: this thesis focuses on the identification of novel neuromodulator targets of human cognition which offer therapeutic promise for cognitive impairment in depression. Chapter 1 of this thesis reviews the evidence which supports the pharmacological targeting of impaired cognition in individuals with depression. This review was informed by interviews (PPI consultations) with individuals with lived experience of depression, helping shape research priorities within this thesis. As a result of this review, promising targets of cognitive function in humans were identified for investigation, including the serotoninergic and histaminergic system. In Chapters 2 and 3, we use a unique approach to increasing synaptic serotonin levels in humans – a selective serotonin releasing agent – to examine its effect on human cognition and emotional processing. In Chapters 4 and 5, the effects of histamine autoreceptor blockade on cognition and neural dynamics in humans are explored. The research covered in Chapters 2–5 employs an experimental medicine approach, where healthy volunteers are used to model the cognitive effects of pharmacological interventions to assess their viability for clinical translation. Chapter 6, the final chapter, unifies the research findings reported within this thesis, placing them in a broader literature context, with suggestions for potential directions of travel for future research. The experimental findings presented in this thesis provide a foundation for future translational research to explore the therapeutic potential of these drug mechanisms within clinical populations.

Actions

Authors

More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Psychiatry
Research group:
Psychopharmacology and Emotion Research Laboratory (PERL)
Oxford college:
Linacre College
Role:
Author
ORCID:
0000-0001-7846-2879

Contributors

Institution:
University of Oxford
Division:
MSD
Department:
Psychiatry
Research group:
Psychopharmacology and Emotion Research Laboratory (PERL)
Oxford college:
Corpus Christi College
Role:
Supervisor
ORCID:
0000-0001-8995-2099
Institution:
University of Oxford
Division:
MSD
Department:
Psychiatry
Research group:
Psychopharmacology and Emotion Research Laboratory (PERL)
Role:
Supervisor
ORCID:
0000-0001-8995-2099


DOI:
Type of award:
DPhil
Level of award:
Doctoral
Awarding institution:
University of Oxford


Language:
English
Keywords:
Subjects:
Pubs id:
2080667
Local pid:
pubs:2080667
Deposit date:
2025-01-25
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP